BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel. Show more
Location: 22 Einstein Street, Ness Ziona, 7414003, Israel | Website: https://www.biomx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
11.23M
52 Wk Range
$0.34 - $3.58
Previous Close
$0.43
Open
$0.38
Volume
2,253,879
Day Range
$0.36 - $0.42
Enterprise Value
19.6M
Cash
20.12M
Avg Qtr Burn
-8.584M
Insider Ownership
19.08%
Institutional Own.
47.70%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BX004 Details Cystic Fibrosis, P. aeruginosa lung infections | Phase 2b Data readout |